The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: TrialNet Natural History Study participants (n = 784) were tested for three autoantibodies (GADA, IA-2A, and mIAA) at their initial screening. Samples from those positive for at least one autoantibody were subsequently tested for ICA and ZnT8A. An autoantibody risk score (ABRS) was developed from a proportional hazards model that combined autoantibody levels from each autoantibody along with their designations of positivity and negativity. RESULTS: The ABRS was strongly predictive of T1D (hazard ratio [with 95% CI] 2.72 [2.23-3.31], P < 0.001). Receiver operating characteristic curve areas (with 95% CI) for the ABRS revealed good predictability (0.84 [0.78-0.90] at 2 years, 0.81 [0.74-0.89] at 3 years, P < 0.001 for both). The composite of levels from the five autoantibodies was predictive of T1D before and after an adjustment for the positivity or negativity of autoantibodies (P < 0.001). The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) predicted T1D more accurately (0.93 [0.88-0.98] at 2 years, 0.91 [0.83-0.99] at 3 years) than either the DPTRS or the ABRS alone (P ≤ 0.01 for all comparisons). CONCLUSIONS: These findings show the importance of considering autoantibody levels in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (55,74,75).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (53,74,75).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A leisurely look at the bootstrap, the jackknife, and cross-validation
Efron, B., & Gong, G. (1983) · The American Statistician · doi:10.1080/00031305.1983.10483087 · Cited by 3,229 · cited 1×
“A leave-one-out procedure was used for cross-validation (19).”
MethodTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854 · cited 1×
“Areas under receiver operating characteristic (ROC) curves, adjusted for length of follow-up (20), were used to assess the accuracy of the scores.”
MethodChristakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes
Wenzlau, J. M., Juhl, K., Yu, L., Moua, O., Sarkar, S. A., Gottlieb, P., Rewers, M., Eisenbarth, G. S., Jensen, J., Davidson, H. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705894104 · Cited by 1,014
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
Self-citationEffects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Ziegler, A. G., Hummel, M., Schenker, M., & Bonifacio, E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 645
The Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314 · cited 1×
“Although confirmatory data are not available, this possibility is suggested by the earlier appearance of autoantibody abnormalities than of overt metabolic abnormalities in the natural history of T1D (30).”
BackgroundKulmala, P., Savola, K., Petersen, J. S., Vähäsalo, P., Karjalainen, J., Löppönen, T., Dyrberg, T., Akerblom, H. K., & Knip, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119879 · Cited by 287
Cited by
Items 101–125 of 125
The Autoimmunity's Footprint in Pediatrics: Type 1 Diabetes, Coeliac Disease, Thyroiditis.
Orzan, A., Novac, C. N., Mihu, M., Tîrgoviște, C. I., & Bălgrădean, M. (2017) · Europe PMC (PubMed Central) · Cited by 1
Tronko, M. D., Mankovskyi, B., & Попова, В. В. (2019) · JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE · doi:10.37621/jnamsu-2019-3-285-295 · Cited by 1
Künstliche Intelligenz und maschinelles Lernen in der Diabetesforschung
Nguyen, P., Ohnmacht, A. J., Galhoz, A., Büttner, M., Theis, F. J., & Menden, M. P. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00817-w · Cited by 1
Gallwitz, B. (2016) · Springer eBooks · doi:10.1007/978-3-642-54676-1_344-1 · Cited by 1
Akel, O., & Lernmark, Å. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch14 · Cited by 4
Autoantibodies as important biomarkers in early diagnosis of type-1 diabetes
Rumano, M., & Sheme, K. (2024) · Journal of Biological Studies · doi:10.62400/jbs.v7i2.9967 · Cited by 1
Aspects of autoantibody epitopes in type 1 diabetes
Skärstrand, H. (2014) · Lund University Publications (Lund University)
Immunology of b-Cell Destruction 37
Lernmark, Å., & Torre, D. L. (2015)
Tronko, M. D., Kp, Z., & Попова, В. В. (2019) · Endokrynologia · doi:10.31793/1680-1466.2019.24-3.203
Predicting Type 1 Diabetes Onset using Novel Survival Analysis with Biomarker Ontology.
Li, Y., Liu, B., Anand, V., Dunne, J. L., Lundgren, M., Ng, K., Rewers, M., Veijola, R., & Ghalwash, M. F. (2020) · PubMed Central · Cited by 1
Immunology of β-Cell Destruction
Lernmark, Å., & Torre, D. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_18-2
Immunology of β-Cell Destruction
Lernmark, Å., & Torre, D. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_18 · Cited by 1
Gallwitz, B. (2020) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_344-2
The influence of type II cytokines in central tolerance
Cattin-Roy, A. N. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/90006
Treatment and prevention of type 1 diabetes in the 21st century
Baidal, D. A., Sosenko, J. M., & Skyler, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00007-3
Self-citationLin, N., Bai, L., Liu, Q., Chen, J., Ren, H., Guan, H., & Lu, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26581607
Honardoost, M. A., Adinatha, A., Schmidt, F., Ranjan, B., Ghaeidamini, M., Rayan, N. A., Gek Liang Lim, M., Joanito, I., Xiao Xuan Lin, Q., Rajagopalan, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25495138
Honardoost, M. A., Adinatha, A., Schmidt, F., Ranjan, B., Ghaeidamini, M., Rayan, N. A., Gek Liang Lim, M., Joanito, I., Xiao Xuan Lin, Q., Rajagopalan, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25495282
Martinez, M. M., Spiliopoulos, L., Salami, F., Agardh, D., Toppari, J., Lernmark, Å., Kero, J. T., Veijola, R., Tossavainen, P. H., Palmu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17870244
Immunothérapie par faibles doses d'IL-2 : potentiel therapeutique dans le diabète de type 1
Pérol, L. (2014) · theses.fr (ABES) · doi:10.70675/ec92b3d1zbfbdz4e97z8339z381d6008e0c8
Relevance of Quantitative Measures of Beta-Cell Function in Clinical Practice
Galderisi, A., Dayan, C. M., Colhoun, H. M., & Gregory, J. M. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552501
“For example, computing progression indices such as the Index60, which is based on fasting glucose and C-peptide and 1 h post-oral glucose load, and the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), which also incorporates BMI and age, can be useful metrics [15, 41–47].”
Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes
Jayabalan, N., Carrión, F., Joshi, K., Huynh, T., & Salomón, C. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70700
“Subsequent work by Xu et al. 79 and Sosenko et al. 80 advanced this framework by integrating immunologic markers with metabolic indices, particularly C‑peptide decline.”
Wouters, A., Mathieu, C., & Gysemans, C. A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104120 · Cited by 1
You, L., Salami, F., Törn, C., Lernmark, Å., Vehik, K., Liu, X., Qiu, P., & Tamura, R. (2026) · Biostatistics · doi:10.1093/biostatistics/kxag018
“Incorporating additional genetic and metabolic risk factors has been shown in previous studies to improve performance in terms of AUC, though in different cohorts (eg Sosenko et al. 2013; Ferrat et al. 2020).”
Metadata
- Authors
- Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., Eisenbarth, G., & Groups, T. T. 1. D. T. A. T. D. P. T. 1. S.
- Affiliations
- University of Miami (US)
- University of Washington (US)
- University of South Florida (US)
- HLA/DNA Laboratory, Barbara Davis Center for Childhood Diabetes, Denver, Colorado
- Western University (CA)
- University of Florida Health (US)
- Corresponding author
- the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2615-2620
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747899
- OpenAlex
- W1992564715
- Cited by
- 123
- References
- 32
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 17 · 2013: 4
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Cambridge University Engineering Department Publications Database (submittedVersion)
- Funders
- American Diabetes Association
- National Institutes of Health (UL1TR000093, 5ul1rr031986-02, HHSN267200800019C, UL1TR001085, UL1TR000130, UL1TR000005, RR025780, DK017047)
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, DK017047, U01DK061040, U01DK085461, U01DK085505, 017047, U01DK085499, UL1-RR-024139, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, UC4DK097835, U01DK085509, U01 DK-061016, P30DK017047)
- National Institute of Child Health and Human Development
- U.S. National Library of Medicine (HHSN267200800019C)
- National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN267200800019C)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- type 1 diabetes, islet autoantibodies, disease prediction, GADA, IA-2A, MiaA, Ica, ZnT8A, autoantibody levels
- MeSH terms
- Adolescent, Adult, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Humans, Male, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.